Overview: Thrombotic Risk Screen Panel
Introduction: The Thrombotic Risk Screen Panel is a diagnostic tool designed for thrombotic risk assessment using plasma samples. In India, young-onset VTE and recurrent thrombosis are increasing due to inherited (Factor V Leiden, prothrombin G20210A) and acquired (lupus anticoagulant) factors, with high prevalence in pregnancy-related events. High morbidity from under-testing in rural/low-SES patients with unprovoked DVT or stroke, limited labs, delayed anticoagulation leading to recurrence or fatal PE. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay/PCR for 4 parameters (Factor V Leiden, prothrombin G20210A, lupus anticoagulant, homocysteine) over 3â€"5 days with high accuracy, valuable for initial thrombophilia risk stratification. This diagnostic falls under coagulation screening and targets patients with VTE, stroke, or pregnancy complications, addressing accurate detection to guide anticoagulation or prophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling focused thrombotic risk profiling and reducing recurrence. Its plasma-based approach ensures reliable genetic/functional assessment.
Other Names: Thromb Risk Pnl.
FDA Status: FDA approved, CLIA certified for immunology/molecular diagnostics, compliant with 2025 standards.
Historical Milestone: Core thrombotic risk screen standard in VTE workup; in India, used in thrombosis clinics.
Purpose: The test assesses 4 parameters including Factor V Leiden to guide thrombotic risk screening, detect key defects, inform anticoagulation.
Test Parameters: 1. Factor V Leiden, 2. Prothrombin G20210A, 3. Lupus Anticoagulant, 4. Homocysteine.
Pretest Condition: No fasting required; patients should have thrombosis history.
Specimen: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on VTE, stroke, pregnancy loss.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected risk including recurrence, benefits of screening, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using immunoassay/PCR by trained personnel to ensure sterile technique and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive Factor V Leiden/prothrombin mutation increases thrombotic risk, necessitating specialist input.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: D-dimer, imaging for VTE confirmation.
Test Limitations: Focused screen; comprehensive approach required.
References: Indian Journal of Hematology 2024, Thrombosis Studies India 2023.
